VEGFA and age-related macular degeneration: In AMD-MANAGE, a mean number of 5.5 anti-VEGF injections in the initial 12-month study period was administered; 41.9% of the patients gained ≥ 5 letters in BCVA at Month 3 with an overall 84.1% completing the loading dose, and the BCVA gain at Month 3 was only sustained until Month 12 in patients, who have received ≥ 5 annual injections, but not < 5 annual injections [18].